Сакам да ве известам дека два труда од нашиот тим се цитирани во списанието International Journal of Neuropsychopharmacology, поточно во трудот The need for a comprehensive molecular
characterization of autism spectrum disorders. Трудот има број doi:10.1017/S146114571300117X. Наши трудови кои се цитирани во него се:
Spiroski M, Trajkovski V, Trajkov D, Petlichkovski A, Efinska-Mladenovska O, Hristomanova S, Djulejic E, Paneva M, Bozhikov J (2009) Family analysis of immunoglobulin classes and subclasses in children with autistic disorder. Bosn J Basic Med Sci 9:283–289.
Trajkovski V, Ajdinski L, Spiroski M (2004) Plasma concentration of immunoglobulin classes and subclasses in children with autism in the Republic of Macedonia: retrospective study. Croat Med J 45:746–749.
Бидејќи трудот не е со отворен пристап и затоа ви го приложувам само резимето. Инаку списанието е во групата на Cambridge Journals што уште повеќе го зголемува значењето на цитираноста.
The need for a comprehensive molecular characterization of autism spectrum disorders
a1 Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK
a2 Department of Neuroscience, Erasmus Medical Centre, Rotterdam, The Netherlands
AbstractAutism spectrum disorders (ASD) are a heterogeneous group of disorders which have complex behavioural phenotypes. Although ASD is a highly heritable neuropsychiatric disorder, genetic research alone has not provided a profound understanding of the underlying causes. Recent developments using biochemical tools such as transcriptomics, proteomics and cellular models, will pave the way to gain new insights into the underlying pathological pathways. This review addresses the state-of-the-art in the search for molecular biomarkers for ASD. In particular, the most important findings in the biochemical field are highlighted and the need for establishing streamlined interaction between behavioural studies, genetics and proteomics is stressed. Eventually, these approaches will lead to suitable translational ASD models and, therefore, a better disease understanding which may facilitate novel drug discovery efforts in this challenging field.
Key words: Autism spectrum disorder (ASD); biomarker; omic platforms; pre-clinical models
Post a Comment